Collegium Pharmaceutical, Inc. Common Stock (COLL) — Analysis Summary
Collegium Pharmaceutical, Inc. Common Stock (COLL) has a market cap of $742.59M with year-over-year revenue growth of +23.6%. Net margin stands at 8.1%. The stock trades at a P/E ratio of 15.5.
Key Takeaways
- Revenue changed +23.6% year-over-year
- Net margin of 8.1%
- P/E ratio of 15.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, COLL posted revenue growth of +23.6% and trades at a P/E of 15.5.
Collegium Pharmaceutical, Inc. Common Stock (COLL)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Interest coverage at 2.1x — limited headroom for earnings decline
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
423
Headquarters
STOUGHTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.